Tulathromycin, sold under the brand name Draxxin among others, is a

macrolide antibiotic The Macrolides are a class of natural products that consist of a large macrocycle, macrocyclic lactone ring to which one or more deoxy sugars, usually cladinose and desosamine, may be attached. The lactone rings are usually 14-, 15-, or 16-memb ...

used to treat bovine respiratory disease in cattle and swine respiratory disease in pigs.

Medical uses

Tulathromycin is indicated for: Cattle: Treatment and metaphylaxis of bovine respiratory disease (BRD) associated with ''

Mannheimia haemolytica ''Mannheimia'' is a Gram-negative, anaerobic, non- spore-forming and non-motile bacterial genus from the family Pasteurellaceae The Pasteurellaceae comprise a large family of Gram-negative bacteria. Most members live as commensals on mucosal ...

'', '' Pasteurella multocida'', ''

Histophilus somni ''Histophilus somni'' is a non-motile, gram-negative, rod or coccobacillus shaped, facultative anaerobe bacteria belonging to the family Pasteurellaceae. Prior to 2003, it was thought ''Haemophilus somnus'', ''Histophilus ovis'', and ''Histophi ...

'', and ''

Mycoplasma bovis ''Mycoplasma bovis'' is one of 126 species of genus '' Mycoplasma''. It is the smallest living cell and anaerobic organism in nature. It does not contain any cell wall and is therefore resistant to penicillin and other beta lactam antibiotics. ...

'' sensitive to tulathromycin. Treatment of infectious bovine keratoconjunctivitis (IBK) associated with ''

Moraxella bovis ''Moraxella bovis'' is a Gram-negative, aerobic, oxidase-positive rod-shaped bacterium. It is the cause of infectious bovine keratoconjunctivitis, a contagious ocular disease of cattle,George M. Garrity: '' Bergey's Manual of Systematic Bacterio ...

'' sensitive to tulathromycin. Pigs: Treatment and metaphylaxis of swine respiratory disease (SRD) associated with ''

Actinobacillus pleuropneumoniae ''Actinobacillus pleuropneumoniae'' (previously ''Haemophilus pleuropneumoniae''), is a Gram-negative, facultative anaerobic, respiratory pathogen found in pigs. It was first reported in 1957, and was formally declared to be the causative agent o ...

'', '' Pasteurella multocida'', ''

Mycoplasma hyopneumoniae ''Mycoplasma hyopneumoniae'' is a species of bacteria known to cause the disease porcine enzootic pneumonia, a highly contagious and chronic disease affecting pigs. As with other mollicutes, ''M. hyopneumoniae'' is small in size (400–1200 ...

'', ''

Haemophilus parasuis ''Haemophilus'' is a genus of Gram-negative, pleomorphic, coccobacilli bacteria belonging to the family Pasteurellaceae. While ''Haemophilus'' bacteria are typically small coccobacilli, they are categorized as pleomorphic bacteria because of ...

'', and ''

Bordetella bronchiseptica ''Bordetella bronchiseptica'' is a small, gram-negative, rod-shaped bacterium of the genus ''Bordetella''. It can cause infectious bronchitis in dogs and other animals, but rarely infects humans. Closely related to '' B. pertussis''—the obl ...

'' sensitive to tulathromycin. Sheep: Treatment of the early stages of infectious pododermatitis (foot rot) associated with virulent ''Dichelobacter nodosus'' requiring systemic treatment.

Society and culture

Legal status

Tulathromycin (brand name Draxxin) was approved for medical use in the European Union in November 2003. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged. Tulathromycin (brand names Tulissin and Tulaven) was approved for medical use in the European Union in April 2020. On 16 July 2020, the Committee for Medicinal Products for Veterinary Use (CVMP) adopted positive opinions, recommending the granting of marketing authorizations for the veterinary medicinal products Increxxa and Tulinovet solutions for injection for cattle, pigs and sheep. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged. The applicant for Increxxa is Elanco GmbH. The applicant for Tulinovet is VMD N.V. Increxxa was approved for veterinary use in the European Union in September 2020.

Brand names

It is marketed by

Pfizer Inc. Pfizer Inc. ( ) is an American Multinational corporation, multinational Pharmaceutical industry, pharmaceutical and biotechnology corporation headquartered on 42nd Street (Manhattan), 42nd Street in Manhattan, Manhattan, New York City. The co ...

under the brand name Draxxin. It is marketed by Bimeda Inc. under the brand name Macrosyn, and by Merck & Co. under the brand name Arovyn. It is also sold under the brand name Increxxa.

References

External links

* Macrolide antibiotics Drugs developed by Pfizer Drugs developed by Merck & Co. {{Veterinary-med-stub